Alendronate sodium 40 mg Oral Tablet
RxNorm 904405
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 904405 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: alendronate sodium 40 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCD
Semantic Clinical Drug (SCD):
Alendronic acid 40 mg Oral Tablet
(Atom ID: 12330961)
PSN
Prescribable Name (PSN):
Alendronate sodium 40 mg Oral Tablet
(Atom ID: 6365075)
PT
Designated preferred name (PT):
Alendronic acid (as alendronate sodium) 40 mg oral tablet
(Atom ID: 12664513)
SY
Synonym (SY):
Alendronic acid 40 mg (as alendronate sodium 52.21 mg) Oral Tablet
(Atom ID: 8691834)
FN
Full form of descriptor (FN):
Product containing precisely alendronic acid (as alendronate sodium) 40 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 12665683)
Patient Education
Alendronate
Alendronate is used to treat and prevent osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause (''change of life,'' end of menstrual periods) and to treat osteoporosis in men. Alendronate is also used to treat osteoporosis in men and women who are taking corticosteroids (a type of medication that may cause osteoporosis in some patients). Alendronate is also used to treat Paget's disease of bone (a condition in which the bones are soft and weak and may be deformed, painful, or easily broken). Alendronate is in a class of medications called bisphosphonates. It works by preventing bone breakdown and increasing bone density (thickness).
[Learn More]
* Please review the disclaimer below.